TAA-Specific CTLs is under clinical development by Marker Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TAA-Specific CTLs’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TAA-Specific CTLs overview

Tumor Associated Antigen (TAA) specific cytotoxic T lymphocytes are under development for the treatment of solid tumors such as breast cancer, metastatic adenocarcinoma of the pancreas, Hodgkin, non-Hodgkin lymphoma, sarcoma and multiple myeloma. It is administered as intravenous injection. It constitutes tumor associated antigen (TAA)-specific cytotoxic T lymphocytes which act by targeting on cancer cells which express NY-ESO-1, MAGEA4, PRAME, Survivin and SSX tumor associated antigens.

Marker Therapeutics overview

Marker Therapeutics is a clinical-stage immuno-oncology company that carries out the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company’s pipeline products include MT-401, which is used for the treatment of post-transplant AML and MT-601, which is used for the treatment of advanced unresectable pancreatic cancer. It also provides Multi-Antigen Targeted (MultiTAA) technology that utilizes a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient’s blood. Marker Therapeutics carries out several clinical studies including acute myeloid leukemia, non-Hodgkin’s lymphoma, multiple myeloma and breast cancer. Marker Therapeutics is headquartered in Houston, Texas, the US.

For a complete picture of TAA-Specific CTLs’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.